fda bpc-157 status 2026 Exciting news for peptides coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for FDA reviews BPC-157, TB-500 and

Examples of FDA-approved peptides: Semaglutide (Ozempic, Wegovy): Approved for: Type 2 diabetes (Ozempic), obesity (Wegovy) Legal status: Prescription required, completely legal Schedule: Not a controlled substance Availability: Through licensed pharmacies with valid prescription Tirzepatide (Mounjaro, Zepbound): Approved for: Type 2 diabetes (Mounjaro), obesity (Zepbound) Legal status: Prescription required, completely legal Recent: Approved 2022-2023 Tesamorelin (Egrifta): Approved for: HIV-associated lipodystrophy (belly fat) Legal status: Prescription required, completely legal Sermorelin, CJC-1295 (with DAC - as Tesamorelin precursor): Some formulations approved for specific conditions Generally require prescription through compounding pharmacies PT-141 (Bremelanotide/Vyleesi): Approved for: Female sexual dysfunction Legal status: Prescription required, completely legal Key point: If a peptide is FDA-approved and you have a legitimate prescription, it's 100% legal

It's like calling in the construction crew and giving them an express lane to the worksite

Third parties operate under their own terms and privacy practices

Still bloated, still exhausted, still no real answers